Literature DB >> 17109474

U-500 insulin: why, when and how to use in clinical practice.

R Garg1, V Johnston, P G McNally, M J Davies, I G Lawrence.   

Abstract

Some patients with type 2 diabetes mellitus (T2DM) have severe insulin resistance. Their insulin requirements are significantly greater. These patients need to take 2-3 injections at the same time to take the correct insulin dose or to redial the insulin pen. When daily insulin requirements are in excess of 300 units/day, the volume of the injected insulin becomes an issue. Large-volume injection can cause discomfort and lead to poor concordance with treatment. Using high-strength insulin e.g. U-500 insulin can reduce the volume of the injected insulin. Despite publications of small case reports or case series, no universal guidelines exist on the use of U-500 insulin. We discuss common sense approaches when considering the use of U-500 insulin in clinical practice. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17109474     DOI: 10.1002/dmrr.709

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  12 in total

1.  U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes.

Authors:  Jolene Brown Lowery; Amy C Donihi; Mary T Korytkowski
Journal:  Diabetes Technol Ther       Date:  2012-02-24       Impact factor: 6.118

2.  Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.

Authors:  Joanna W Chung; Melody L Hartzler; Ashley Smith; Jessica Hatton; Kristi Kelley
Journal:  P T       Date:  2018-04

3.  A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections.

Authors:  Juan P Frias; Bruce W Bode; Timothy S Bailey; Mark S Kipnes; Rocco Brunelle; Steven V Edelman
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

Review 4.  Inpatient management of women with gestational and pregestational diabetes in pregnancy.

Authors:  Etoi A Garrison; Shubhada Jagasia
Journal:  Curr Diab Rep       Date:  2014-02       Impact factor: 4.810

Review 5.  Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus.

Authors:  Alexandria M Dailey; Lisa R Tannock
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

6.  Clinical efficacy and patient satisfaction with U-500 insulin use.

Authors:  Alexandria M Dailey; Sarah Williams; Deepa Taneja; Lisa R Tannock
Journal:  Diabetes Res Clin Pract       Date:  2010-03-11       Impact factor: 5.602

7.  Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.

Authors:  Amparo de la Peña; Xiaosu Ma; Shobha Reddy; Fernando Ovalle; Richard M Bergenstal; Jeffrey A Jackson
Journal:  J Diabetes Sci Technol       Date:  2014-05-12

8.  Type 2 diabetes: uses of thiazolidinediones and insulin.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

9.  Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study.

Authors:  Elizabeth L Eby; Bradley H Curtis; Steven C Gelwicks; Robert C Hood; Iskandar Idris; Anne L Peters; Richard M Bergenstal; Jeffrey A Jackson
Journal:  BMJ Open Diabetes Res Care       Date:  2015-04-30

10.  Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.

Authors:  Stephen C L Gough; Anuj Bhargava; Rajeev Jain; Henriette Mersebach; Søren Rasmussen; Richard M Bergenstal
Journal:  Diabetes Care       Date:  2013-05-28       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.